Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Other Operating Expenses (2016 - 2025)

Moleculin Biotech's Other Operating Expenses history spans 10 years, with the latest figure at $9000.0 for Q4 2025.

  • Quarterly results put Other Operating Expenses at $9000.0 for Q4 2025, down 70.97% from a year ago — trailing twelve months through Dec 2025 was $90000.0 (down 28.0% YoY), and the annual figure for FY2025 was -$10000.0, down 107.94%.
  • Other Operating Expenses for Q4 2025 was $9000.0 at Moleculin Biotech, down from $21000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $44000.0 in Q1 2021 to a low of $9000.0 in Q4 2025.
  • The 5-year median for Other Operating Expenses is $32000.0 (2022), against an average of $31800.0.
  • The sharpest move saw Other Operating Expenses rose 9.38% in 2023, then crashed 70.97% in 2025.
  • Year by year, Other Operating Expenses stood at $34000.0 in 2021, then dropped by 5.88% to $32000.0 in 2022, then rose by 9.38% to $35000.0 in 2023, then dropped by 11.43% to $31000.0 in 2024, then crashed by 70.97% to $9000.0 in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $9000.0, $21000.0, and $29000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.